Cognitive Enhancement Stack

226 PubMed citations and a prescription approval in Russia. That track record separates Semax (Met-Glu-His-Phe-Pro-Gly-Pro, ACTH 4-10 analog) from most peptides in the nootropic category. The mechanism is centered on BDNF. Dolotov and colleagues confirmed that a single Semax injection at 50 mcg/kg produced a 3-fold increase in BDNF mRNA and a 1.4-fold increase in BDNF protein in the rat hippocampus (PMID 16996037). A separate group showed binding-specific increases in BDNF protein in the basal forebrain (PMID 16635254). Beyond neurotrophins, Semax activates dopaminergic and serotonergic systems without touching cortisol, unlike its parent molecule ACTH. In practice, the community doses 300 to 600 mcg intranasally each morning for 10 to 14 days. Thousands of user reports across r/Peptides, r/nootropics, and Longecity describe improved focus, verbal fluency, and working memory starting within the first few days. The Selank stack (300 mcg of each, intranasal AM) is the most popular combination, adding anxiolytic balance to the dopaminergic stimulation. Lebedeva and colleagues tracked 110 stroke patients on Semax and confirmed increased plasma BDNF. A 2025 study in transgenic Alzheimer's mice showed reduced amyloid plaques (PMID 41479572). Another 2025 paper in the British Journal of Pharmacology identified a new mu-opioid receptor mechanism for spinal cord injury recovery (PMID 40692165). The science is expanding, but it still leans heavily on animal models and small Russian clinical samples. No placebo-controlled RCT has been run in healthy adults at any dose.

A 192-patient randomized trial tested this peptide head-to-head against medazepam for generalized anxiety disorder and found comparable anxiolytic effects (Zozulya et al. 2008, PMID 18454096). A second study compared it directly to phenazepam with similar results and a cleaner side effect profile (PMID 25176261). That level of clinical evidence puts Selank ahead of most research peptides. Selank (full sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its mechanism hits multiple pathways at once. It inhibits enkephalinase, which extends the half-life of your body's own enkephalins. It modulates GABA receptor expression (confirmed at the gene level in PMID 26847159). And it influences serotonin pathways and upregulates BDNF. The practical result is an anxiolytic that doesn't sedate you or dull your thinking. Users across dozens of Reddit threads on r/peptides and r/Nootropics describe it as "taking the edge off" while leaving focus intact. The most common protocol mirrors Russian clinical trial design: 250 to 500 mcg daily for 2 to 4 weeks, then cycling off for an equal period. Intranasal delivery has become the community's preferred route for its faster onset (15 to 30 min) and convenience. Two honest caveats: every published clinical trial originates from Russian academic institutions, with no independent Western replication to date. And the plasma half-life is very short (roughly 2 to 3 minutes IV), which means the mechanism behind its prolonged effect still isn't fully explained. The FDA removed Selank acetate from the Category 2 bulks list in September 2024; it remains research-only in the US.